Your institution may have access to this item. Find your institution then sign in to continue.
Title
Recapturing disease response: A phase 2 study of carfilzomib 56 mg/m<sup>2</sup> in patients with relapsed or refractory multiple myeloma who have progressed on carfilzomib 27 mg/m<sup>2</sup>.